Revenue for the three months ended March 31, 2026, was $3.16 million, down 5% from $3.32 million in the prior-year period. Net loss for the quarter was $2.6 million, compared to a net loss of $3.96 million in Q1 2025. Gross margin compressed to 38% from 56% in the prior-year period, primarily due to higher costs associated with the new Teleradiology service line. Operating expenses increased to $4.17 million, up 13% from $3.69 million in Q1 2025. Cash and cash equivalents decreased significantly to $1.35 million as of March 31, 2026, from $5.27 million at year-end 2025.